MyMD Pharmaceuticals Files 8-K: Material Agreements & Bylaw Changes
Ticker: QCLS · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, bylaws
TL;DR
MyMD Pharma filed an 8-K detailing new material agreements and changes to bylaws, impacting security holder rights.
AI Summary
MyMD Pharmaceuticals, Inc. announced on March 4, 2024, that it entered into a material definitive agreement. The company also reported material modifications to the rights of its security holders and amendments to its articles of incorporation or bylaws. This filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements and potential changes to shareholder rights, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce significant changes and uncertainties for investors.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- March 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Akers Biosciences, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by MyMD Pharmaceuticals?
The filing states that MyMD Pharmaceuticals, Inc. entered into a material definitive agreement on March 4, 2024, but the specific details of this agreement are not provided in the provided text.
What specific modifications were made to the rights of MyMD Pharmaceuticals' security holders?
The filing indicates material modifications to the rights of security holders, but the exact nature of these modifications is not detailed in the provided text.
Were there any amendments to MyMD Pharmaceuticals' articles of incorporation or bylaws?
Yes, the filing explicitly lists 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item of information, indicating such amendments have occurred.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 4, 2024.
What was MyMD Pharmaceuticals, Inc. formerly known as?
MyMD Pharmaceuticals, Inc. was formerly known as Akers Biosciences, Inc.
Filing Stats: 879 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2024-03-07 16:30:39
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex2-1.htm (EX-2.1) — 53KB
- ex3-1.htm (EX-3.1) — 577KB
- ex3-2.htm (EX-3.2) — 280KB
- 0001493152-24-009220.txt ( ) — 1294KB
- mymd-20240304.xsd (EX-101.SCH) — 3KB
- mymd-20240304_lab.xml (EX-101.LAB) — 33KB
- mymd-20240304_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: March 7, 2024 By: /s/ Christopher Chapman, M.D. Christopher Chapman, M.D. President and Chief Medical Officer